Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary

Alan J. Garber, Yehuda Handelsman, George Grunberger, Daniel Einhorn, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Michael A. Bush, Ralph A. DeFronzo, Jeffrey R. Garber, W. Timothy Garvey, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Leigh Perreault, Paul D. Rosenblit, Susan Samson, Guillermo E. Umpierrez

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

Original languageEnglish (US)
Pages (from-to)107-139
Number of pages33
JournalEndocrine Practice
Volume26
Issue number1
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary'. Together they form a unique fingerprint.

Cite this